ArriVent BioPharma, Inc.
AVBP
$20.11
$0.231.16%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Total Cash And Short-Term Investments | 235.69M | 176.08M | 218.86M | 282.86M | 298.67M |
Total Receivables | 505.00K | 505.00K | 500.00K | 500.00K | 750.00K |
Inventory | -- | -- | -- | -- | -- |
Prepaid Expenses | 787.00K | 1.23M | 407.00K | 1.14M | 1.23M |
Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
Other Current Assets | 13.17M | 7.98M | 7.21M | 7.90M | 7.87M |
Total Current Assets | 250.15M | 185.79M | 226.98M | 292.40M | 308.51M |
|
|||||
Total Current Assets | 250.15M | 185.79M | 226.98M | 292.40M | 308.51M |
Net Property, Plant & Equipment | 85.00K | 120.00K | 154.00K | 187.00K | 219.00K |
Long-term Investments | -- | -- | -- | -- | -- |
Goodwill | -- | -- | -- | -- | -- |
Total Other Intangibles | -- | -- | -- | -- | -- |
Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
Total Other Assets | 479.00K | 176.00K | 126.00K | 126.00K | 125.00K |
Total Assets | 269.51M | 215.50M | 274.94M | 292.71M | 308.86M |
|
|||||
Total Accounts Payable | 4.06M | 4.36M | 3.78M | 4.65M | 3.81M |
Total Accrued Expenses | 15.48M | 8.45M | 13.33M | 10.36M | 8.13M |
Short-term Debt | -- | -- | -- | -- | -- |
Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
Finance Division Debt Current | 98.00K | 138.00K | 162.00K | 157.00K | 152.00K |
Total Finance Division Other Current Liabilities | -- | -- | -- | -- | -- |
Total Other Current Liabilities | -- | -- | -- | -- | -- |
Total Current Liabilities | 19.64M | 12.95M | 17.27M | 15.16M | 12.10M |
|
|||||
Total Current Liabilities | 19.64M | 12.95M | 17.27M | 15.16M | 12.10M |
Long-Term Debt | -- | -- | -- | -- | -- |
Short-term Debt | -- | -- | -- | -- | -- |
Capital Leases | -- | -- | 14.00K | 56.00K | 98.00K |
Finance Division Debt Non Current | -- | -- | -- | -- | -- |
Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
Total Other Liabilities | -- | -- | -- | -- | -- |
Total Liabilities | 19.64M | 12.95M | 17.29M | 15.22M | 12.20M |
|
|||||
Common Stock & APIC | 584.01M | 505.28M | 496.20M | 495.19M | 493.80M |
Retained Earnings | -334.12M | -302.72M | -238.33M | -217.70M | -197.14M |
Treasury Stock & Other | -18.00K | -17.00K | -211.00K | -- | -- |
Total Common Equity | 249.87M | 202.54M | 257.65M | 277.49M | 296.66M |
|
|||||
Preferred Stock Redeemable | -- | -- | -- | -- | -- |
Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
Preferred Stock Convertible | -- | -- | -- | -- | -- |
Preferred Stock, Others | -- | -- | -- | -- | -- |
Total Preferred Equity | -- | -- | -- | -- | -- |
|
|||||
Total Common Equity | 249.87M | 202.54M | 257.65M | 277.49M | 296.66M |
Total Preferred Equity | -- | -- | -- | -- | -- |
Total Minority Interest | -- | -- | -- | -- | -- |
Total Equity | 249.87M | 202.54M | 257.65M | 277.49M | 296.66M |
|